Cutting-Edge Innovations: Recent Patents in Medicinal Chemistry

Arshleen Kaur; Rajesh K. Singh; Rohit Bhatia

doi:10.2174/0109298673397069250807094444

journal article Mar 01, 2026

Cutting-Edge Innovations: Recent Patents in Medicinal Chemistry

Arshleen Kaur Rajesh K. Singh

Rohit Bhatia

Current Medicinal Chemistry Vol. 33 No. 9 pp. 1867-1871 · Bentham Science Publishers Ltd.

View at Publisher Save 10.2174/0109298673397069250807094444

Topics

No keywords indexed for this article. Browse by subject →

References

9

[1]

Xiao Y.; He Z.; Li W.; Chen D.; Niu X.; Yang X.; Zeng W.; Wang M.; Qian Y.; Su Y.; Luo F.; Chen G.; Liu J.; Sui X.; Zhou X.; Gao Y.; A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapy. Nat Commun 2025,16(1),1388 10.1038/s41467-025-56648-6

[2]

Sharma A.; Narang A.; Kumar N.; Rana R.; Megha; Pooja; Dhir, M.; Gulati, H.K.; Jyoti; Khanna, A.; Singh, J.V.; Kaur, S.; Bedi, P.M.S. CADD based designing and biological evaluation of novel triazole based thiazolidinedione coumarin hybrids as antidiabetic agent. Sci Rep 2025,15(1),4302 10.1038/s41598-025-88944-y

[3]

Schallmayer E.; Isigkeit L.; Elson L.; Müller S.; Knapp S.; Marschner J.A.; Merk D.; Chemogenomics for steroid hormone receptors (NR3). Commun Chem 2025,8(1),29 10.1038/s42004-025-01427-z

[4]

Isaacson S.H.; Espay A.J.; Pahwa R.; Agarwal P.; Shill H.A.; Hui J.; Dashtipour K.; Lew M.; Qin P.; Formella A.E.; Ceresoli B.G.; LeWitt P.A.; Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study. J Parkinsons Dis 2025,15(2) 10.1177/1877718x241310727

[5]

Tepper, S.; Richard, L.; Angad, Chh.; Caroline, S; Gregory, P.; Herriot, T. Combined Efficacy and Safety of AXS-07 (MOSEICTM Meloxicam and Rizatriptan) in Two Phase 3 Clinical Trials (P7-12.002). Neurology, 2024,102(7 supplement 1) 10.1212/wnl.0000000000205655

[6]

Osteen J.D.; Immani S.; Tapley T.L.; Indersmitten T.; Hurst N.W.; Healey T.; Aertgeerts K.; Negulescu P.A.; Lechner S.M.; Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain. Pain Ther 2025,14(2),655-674 10.1007/s40122-024-00697-0

[7]

Shadur B.;; NasserEddin, A.; Zaidman, I.; Schejter, Y.D.; Even-Or, E.; Berkun, Y.; Meyts, I.; Hmedat, H.; Sulaiman, A.; Tangye, S.G.; Stepensky, P. Successful haematopoietic stem cell transplantation for lrba deficiency with fludarabine, treosulfan, and thiotepa-based conditioning. J Clin Immunol, 2025,45(1),3 10.1007/s10875-024-01770-1

[8]

Ritzau O.V.; Celltrion receives positive chmp opinion for three biosimilars in the European union. Available from: https://www.celltrion.com/en-us/company/media-center/press-release/36202024

[9]

Rashid M.A.; New Drug Approval Vol. 28 (1). Bangladesh Pharmaceutical Journal 2025,28(1),127-131

Metrics

0

Citations

9

References

Details

Published: Mar 01, 2026
Vol/Issue: 33(9)
Pages: 1867-1871

Authors

A

Arshleen Kaur

Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India

R

Rajesh K. Singh

Department ofPharmaceutical Chemistry, Shivalik College of Pharmacy, Nangal, Rupnagar, 140126, Punjab, India

R

Rohit Bhatia

Chitkara College of Pharmacy, Chitkara University, Rajpura, 140401, Punjab, India

Cite This Article

Arshleen Kaur, Rajesh K. Singh, Rohit Bhatia (2026). Cutting-Edge Innovations: Recent Patents in Medicinal Chemistry. Current Medicinal Chemistry, 33(9), 1867-1871. https://doi.org/10.2174/0109298673397069250807094444

Cutting-Edge Innovations: Recent Patents in Medicinal Chemistry

You May Also Like